{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:08:21Z","timestamp":1779062901732,"version":"3.51.4"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Ministry of Food and Drug Safety, Republic of Korea","award":["23202MFDS136"],"award-info":[{"award-number":["23202MFDS136"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-026-01424-w","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T07:10:42Z","timestamp":1774422642000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating varicella-zoster virus vaccine immunogenicity through Fc-mediated antibody functions: the roles of ADCP and ADCC"],"prefix":"10.1038","volume":"11","author":[{"given":"Sivilay","family":"Xayaheuang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Young","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunhwa","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung-Min","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok-Tae","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun-Jeong","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Soo","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Young","family":"Bang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han Sol","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ok Sarah","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Yun","family":"Noh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"So-Hee","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hosun","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"1424_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/(SICI)1096-9071(199709)53:1<63::AID-JMV11>3.0.CO;2-Y","volume":"53","author":"M Haumont","year":"1997","unstructured":"Haumont, M. et al. Neutralizing antibody responses induced by varicella-zoster virus gE and gB glycoproteins following infection, reactivation or immunization. J. Med. Virol. 53, 63\u201368 (1997).","journal-title":"J. Med. Virol."},{"key":"1424_CR2","doi-asserted-by":"publisher","first-page":"6776","DOI":"10.1016\/j.vaccine.2019.09.031","volume":"37","author":"H Asada","year":"2019","unstructured":"Asada, H. VZV-specific cell-mediated immunity, but not humoral immunity, correlates inversely with the incidence of herpes zoster and the severity of skin symptoms and zoster-associated pain: The SHEZ study. Vaccine 37, 6776\u20136781 (2019).","journal-title":"Vaccine"},{"key":"1424_CR3","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1086\/528696","volume":"197","author":"MJ Levin","year":"2008","unstructured":"Levin, M. J. et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J. Infect. Dis. 197, 825\u2013835 (2008).","journal-title":"J. Infect. Dis."},{"key":"1424_CR4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1542\/peds.18.1.109","volume":"18","author":"RA Good","year":"1956","unstructured":"Good, R. A. & Zak, S. J. Disturbances in gamma globulin synthesis as experiments of nature. Pediatrics 18, 109\u2013149 (1956).","journal-title":"Pediatrics"},{"key":"1424_CR5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jim.2015.07.011","volume":"426","author":"K Hayashida","year":"2015","unstructured":"Hayashida, K. et al. Evaluation of varicella zoster virus-specific cell-mediated immunity by using an interferon-gamma enzyme-linked immunosorbent assay. J. Immunol. Methods 426, 50\u201355 (2015).","journal-title":"J. Immunol. Methods"},{"key":"1424_CR6","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1093\/infdis\/jir660","volume":"204","author":"T Banovic","year":"2011","unstructured":"Banovic, T. et al. Disseminated varicella infection caused by varicella vaccine strain in a child with low invariant natural killer T cells and diminished CD1d expression. J. Infect. Dis. 204, 1893\u20131901 (2011).","journal-title":"J. Infect. Dis."},{"key":"1424_CR7","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.jpeds.2004.11.022","volume":"146","author":"A Etzioni","year":"2005","unstructured":"Etzioni, A. et al. Fatal varicella associated with selective natural killer cell deficiency. J. Pediatr. 146, 423\u2013425 (2005).","journal-title":"J. Pediatr."},{"key":"1424_CR8","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1086\/378503","volume":"188","author":"O Levy","year":"2003","unstructured":"Levy, O. et al. Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells. J. Infect. Dis. 188, 948\u2013953 (2003).","journal-title":"J. Infect. Dis."},{"key":"1424_CR9","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1086\/426866","volume":"191","author":"MT Vossen","year":"2005","unstructured":"Vossen, M. T. et al. Absence of circulating natural killer and primed CD8+ cells in life-threatening varicella. J. Infect. Dis. 191, 198\u2013206 (2005).","journal-title":"J. Infect. Dis."},{"key":"1424_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/imr.13091","volume":"310","author":"D Goldblatt","year":"2022","unstructured":"Goldblatt, D., Alter, G., Crotty, S. & Plotkin, S. A. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunol. Rev. 310, 6\u201326 (2022).","journal-title":"Immunol. Rev."},{"key":"1424_CR11","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.chom.2022.03.029","volume":"30","author":"SI Richardson","year":"2022","unstructured":"Richardson, S. I. et al. SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals. Cell Host Microbe 30, 880\u2013886.e884 (2022).","journal-title":"Cell Host Microbe"},{"key":"1424_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100275","volume":"2","author":"J Dufloo","year":"2021","unstructured":"Dufloo, J. et al. Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies. Cell Rep. Med 2, 100275 (2021).","journal-title":"Cell Rep. Med"},{"key":"1424_CR13","doi-asserted-by":"publisher","first-page":"107624","DOI":"10.1016\/j.celrep.2020.107624","volume":"31","author":"BK Felber","year":"2020","unstructured":"Felber, B. K. et al. Co-immunization of DNA and protein in the same anatomical sites induces superior protective immune responses against SHIV challenge. Cell Rep. 31, 107624 (2020).","journal-title":"Cell Rep."},{"key":"1424_CR14","doi-asserted-by":"publisher","first-page":"e01865","DOI":"10.1128\/JVI.01865-18","volume":"93","author":"R Keshwara","year":"2019","unstructured":"Keshwara, R. et al. A recombinant Rabies virus expressing the Marburg virus glycoprotein is dependent upon antibody-mediated cellular cytotoxicity for protection against Marburg virus disease in a murine model. J. Virol. 93, e01865\u201301818 (2019).","journal-title":"J. Virol."},{"key":"1424_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29136","volume":"95","author":"D Chen","year":"2023","unstructured":"Chen, D. et al. Reduced neutralization and Fc effector function to Omicron subvariants in sera from SARS-CoV-1 survivors after two doses of CoronaVac plus one dose subunit vaccine. J. Med. Virol. 95, e29136 (2023).","journal-title":"J. Med. Virol."},{"key":"1424_CR16","first-page":"3040","volume":"15","author":"A Bouayad","year":"2023","unstructured":"Bouayad, A. Multifaceted roles of Fcgamma receptors in COVID-19 and vaccine responses. Am. J. Transl. Res 15, 3040\u20133059 (2023).","journal-title":"Am. J. Transl. Res"},{"key":"1424_CR17","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1093\/infdis\/jiab540","volume":"225","author":"JM Diez","year":"2022","unstructured":"Diez, J. M. et al. Anti-severe acute respiratory syndrome coronavirus 2 hyperimmune immunoglobulin demonstrates potent neutralization and antibody-dependent cellular cytotoxicity and phagocytosis through N and S proteins. J. Infect. Dis. 225, 938\u2013946 (2022).","journal-title":"J. Infect. Dis."},{"key":"1424_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00545-2","volume":"7","author":"SY Park","year":"2022","unstructured":"Park, S. Y. et al. Development of antibody-dependent cellular cytotoxicity in response to recombinant and live-attenuated herpes zoster vaccines. NPJ Vaccines 7, 123 (2022).","journal-title":"NPJ Vaccines"},{"key":"1424_CR19","doi-asserted-by":"publisher","first-page":"19332","DOI":"10.1073\/pnas.1008248107","volume":"107","author":"Y Zhang","year":"2010","unstructured":"Zhang, Y., Hoppe, A. D. & Swanson, J. A. Coordination of Fc receptor signaling regulates cellular commitment to phagocytosis. Proc. Natl. Acad. Sci. USA. 107, 19332\u201319337 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"1424_CR20","first-page":"11","volume":"11","author":"C Watzl","year":"2010","unstructured":"Watzl, C. & Long, E. O. Signal transduction during activation and inhibition of natural killer cells. Curr. Protoc. Immunol. Chapter 11, 11\u201319B (2010).","journal-title":"Curr. Protoc. Immunol. Chapter"},{"key":"1424_CR21","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.88529","volume":"1","author":"CD Petro","year":"2016","unstructured":"Petro, C. D. et al. HSV-2 DeltagD elicits FcgammaR-effector antibodies that protect against clinical isolates. JCI Insight 1, e88529 (2016).","journal-title":"JCI Insight"},{"key":"1424_CR22","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abm3151","volume":"14","author":"AG Dias Jr.","year":"2022","unstructured":"Dias, A. G. Jr. et al. Antibody Fc characteristics and effector functions correlate with protection from symptomatic dengue virus type 3 infection. Sci. Transl. Med. 14, eabm3151 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1424_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.chom.2021.11.006","volume":"30","author":"T Zohar","year":"2022","unstructured":"Zohar, T. et al. Upper and lower respiratory tract correlates of protection against respiratory syncytial virus following vaccination of nonhuman primates. Cell Host Microbe 30, 41\u201352.e45 (2022).","journal-title":"Cell Host Microbe"},{"key":"1424_CR24","doi-asserted-by":"publisher","first-page":"4873","DOI":"10.1016\/j.cell.2022.11.012","volume":"185","author":"YC Bartsch","year":"2022","unstructured":"Bartsch, Y. C. et al. Antibody effector functions are associated with protection from respiratory syncytial virus. Cell 185, 4873\u20134886.e4810 (2022).","journal-title":"Cell"},{"key":"1424_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100510","volume":"3","author":"SI Richardson","year":"2022","unstructured":"Richardson, S. I. et al. SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity. Cell Rep. Med. 3, 100510 (2022).","journal-title":"Cell Rep. Med."},{"key":"1424_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.105753","volume":"26","author":"D Geers","year":"2023","unstructured":"Geers, D. et al. Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination. iScience 26, 105753 (2023).","journal-title":"iScience"},{"key":"1424_CR27","first-page":"e00281","volume":"12","author":"OS Adeniji","year":"2021","unstructured":"Adeniji, O. S. et al. COVID-19 severity is associated with differential antibody Fc-mediated innate immune functions. mBio 12, e00281\u201300221 (2021).","journal-title":"mBio"},{"key":"1424_CR28","doi-asserted-by":"publisher","first-page":"682120","DOI":"10.3389\/fimmu.2021.682120","volume":"12","author":"D Paquin-Proulx","year":"2021","unstructured":"Paquin-Proulx, D. et al. Associations between antibody Fc-mediated effector functions and long-term sequelae in Ebola virus survivors. Front. Immunol. 12, 682120 (2021).","journal-title":"Front. Immunol."},{"key":"1424_CR29","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.chom.2016.05.014","volume":"19","author":"CJ Henry Dunand","year":"2016","unstructured":"Henry Dunand, C. J. et al. Both neutralizing and non-neutralizing human H7N9 influenza vaccine-induced monoclonal antibodies confer protection. Cell Host Microbe 19, 800\u2013813 (2016).","journal-title":"Cell Host Microbe"},{"key":"1424_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008064","volume":"15","author":"SI Richardson","year":"2019","unstructured":"Richardson, S. I. et al. IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody. PLoS Pathog. 15, e1008064 (2019).","journal-title":"PLoS Pathog."},{"key":"1424_CR31","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1128\/jcm.20.1.94-98.1984","volume":"20","author":"VA Sundqvist","year":"1984","unstructured":"Sundqvist, V. A., Linde, A. & Wahren, B. Virus-specific immunoglobulin G subclasses in herpes simplex and varicella-zoster virus infections. J. Clin. Microbiol. 20, 94\u201398 (1984).","journal-title":"J. Clin. Microbiol."},{"key":"1424_CR32","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3345\/cep.2021.01564","volume":"65","author":"YH Lee","year":"2022","unstructured":"Lee, Y. H. et al. Global varicella vaccination programs. Clin. Exp. Pediatr. 65, 555\u2013562 (2022).","journal-title":"Clin. Exp. Pediatr."},{"key":"1424_CR33","doi-asserted-by":"publisher","first-page":"e004833","DOI":"10.1136\/bmjopen-2014-004833","volume":"4","author":"K Kawai","year":"2014","unstructured":"Kawai, K., Gebremeskel, B. G. & Acosta, C. J. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open 4, e004833 (2014).","journal-title":"BMJ Open"},{"key":"1424_CR34","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1128\/JCM.38.7.2568-2573.2000","volume":"38","author":"MD de Jong","year":"2000","unstructured":"de Jong, M. D., Weel, J. F., Schuurman, T., Wertheim-van Dillen, P. M. & Boom, R. Quantitation of varicella-zoster virus DNA in whole blood, plasma, and serum by PCR and electrochemiluminescence. J. Clin. Microbiol. 38, 2568\u20132573 (2000).","journal-title":"J. Clin. Microbiol."},{"key":"1424_CR35","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0065-3527(08)60074-3","volume":"46","author":"AM Arvin","year":"1996","unstructured":"Arvin, A. M., Moffat, J. F. & Redman, R. Varicella-zoster virus: aspects of pathogenesis and host response to natural infection and varicella vaccine. Adv. Virus Res. 46, 263\u2013309 (1996).","journal-title":"Adv. Virus Res."},{"key":"1424_CR36","doi-asserted-by":"publisher","first-page":"e87499","DOI":"10.1172\/jci.insight.87499","volume":"2","author":"JG Burel","year":"2017","unstructured":"Burel, J. G., Apte, S. H., Groves, P. L., McCarthy, J. S. & Doolan, D. L. Polyfunctional and IFN-gamma monofunctional human CD4(+) T cell populations are molecularly distinct. JCI Insight 2, e87499 (2017).","journal-title":"JCI Insight"},{"key":"1424_CR37","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/978-1-0716-3754-8_17","volume":"2782","author":"JJ Freen-van Heeren","year":"2024","unstructured":"Freen-van Heeren, J. J. et al. Assessing antigen-specific T cell responses through IFN-gamma Enzyme-Linked Immune Absorbent Spot (ELISpot). Methods Mol. Biol. 2782, 209\u2013226 (2024).","journal-title":"Methods Mol. Biol."},{"key":"1424_CR38","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1093\/infdis\/jiv164","volume":"212","author":"KJ Laing","year":"2015","unstructured":"Laing, K. J. et al. Zoster vaccination increases the breadth of CD4+ T cells responsive to varicella zoster virus. J. Infect. Dis. 212, 1022\u20131031 (2015).","journal-title":"J. Infect. Dis."},{"key":"1424_CR39","doi-asserted-by":"publisher","first-page":"604","DOI":"10.4049\/jimmunol.1700290","volume":"199","author":"A Weinberg","year":"2017","unstructured":"Weinberg, A. et al. Varicella-zoster virus-specific cellular immune responses to the live attenuated zoster vaccine in young and older adults. J. Immunol. 199, 604\u2013612 (2017).","journal-title":"J. Immunol."},{"key":"1424_CR40","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","volume":"217","author":"AL Cunningham","year":"2018","unstructured":"Cunningham, A. L. et al. Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older. J. Infect. Dis. 217, 1750\u20131760 (2018).","journal-title":"J. Infect. Dis."},{"key":"1424_CR41","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1086\/315347","volume":"181","author":"H Asanuma","year":"2000","unstructured":"Asanuma, H., Sharp, M., Maecker, H. T., Maino, V. C. & Arvin, A. M. Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression. J. Infect. Dis. 181, 859\u2013866 (2000).","journal-title":"J. Infect. Dis."},{"key":"1424_CR42","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.immuni.2020.07.020","volume":"53","author":"C Atyeo","year":"2020","unstructured":"Atyeo, C. et al. Distinct early serological signatures track with SARS-CoV-2 survival. Immunity 53, 524\u2013532.e524 (2020).","journal-title":"Immunity"},{"key":"1424_CR43","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.cell.2013.09.061","volume":"155","author":"DH Barouch","year":"2013","unstructured":"Barouch, D. H. et al. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell 155, 531\u2013539 (2013).","journal-title":"Cell"},{"key":"1424_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006987","volume":"14","author":"SI Richardson","year":"2018","unstructured":"Richardson, S. I. et al. HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies. PLoS Pathog. 14, e1006987 (2018).","journal-title":"PLoS Pathog."},{"key":"1424_CR45","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1016\/j.immuni.2021.08.015","volume":"54","author":"I Ullah","year":"2021","unstructured":"Ullah, I. et al. Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy. Immunity 54, 2143\u20132158.e2115 (2021).","journal-title":"Immunity"},{"key":"1424_CR46","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1016\/j.cell.2021.02.026","volume":"184","author":"ES Winkler","year":"2021","unstructured":"Winkler, E. S. et al. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. Cell 184, 1804\u20131820.e1816 (2021).","journal-title":"Cell"},{"key":"1424_CR47","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.cell.2020.10.052","volume":"183","author":"T Zohar","year":"2020","unstructured":"Zohar, T. et al. Compromised humoral functional evolution tracks with SARS-CoV-2 mortality. Cell 183, 1508\u20131519.e1512 (2020).","journal-title":"Cell"},{"key":"1424_CR48","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1442-200X.1991.tb01518.x","volume":"33","author":"T Ihara","year":"1991","unstructured":"Ihara, T. et al. Antibody response determined with antibody-dependent cell-mediated cytotoxicity (ADCC), neutralizing antibody, and varicella skin test in children with natural varicella and after varicella immunization. Acta Paediatr. Jpn. 33, 43\u201349 (1991).","journal-title":"Acta Paediatr. Jpn."},{"key":"1424_CR49","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1542\/peds.80.6.933","volume":"80","author":"Y Asano","year":"1987","unstructured":"Asano, Y. et al. Immunoglobulin subclass antibodies to varicella-zoster virus. Pediatrics 80, 933\u2013936 (1987).","journal-title":"Pediatrics"},{"key":"1424_CR50","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ebiom.2017.01.014","volume":"16","author":"N Jounai","year":"2017","unstructured":"Jounai, N. et al. Age-specific profiles of antibody responses against respiratory syncytial virus infection. EBioMedicine 16, 124\u2013135 (2017).","journal-title":"EBioMedicine"},{"key":"1424_CR51","doi-asserted-by":"publisher","first-page":"5640","DOI":"10.1182\/blood-2012-01-380121","volume":"119","author":"P Bruhns","year":"2012","unstructured":"Bruhns, P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119, 5640\u20135649 (2012).","journal-title":"Blood"},{"key":"1424_CR52","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1126\/scitranslmed.3007736","volume":"6","author":"AW Chung","year":"2014","unstructured":"Chung, A. W. et al. Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci. Transl. Med. 6, 228\u2013238 (2014).","journal-title":"Sci. Transl. Med."},{"key":"1424_CR53","doi-asserted-by":"publisher","first-page":"e36614","DOI":"10.1016\/j.heliyon.2024.e36614","volume":"10","author":"J Lim","year":"2024","unstructured":"Lim, J., Kim, Y., Hwang, J. Y., Lee, K. M. & Park, H. Evaluation of flow cytometry-based fluorescent antibody to membrane antigen test to measure the humoral immunity against the varicella-zoster virus. Heliyon 10, e36614 (2024).","journal-title":"Heliyon"},{"key":"1424_CR54","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/cyto.a.23348","volume":"93","author":"J Pollara","year":"2018","unstructured":"Pollara, J. et al. Application of area scaling analysis to identify natural killer cell and monocyte involvement in the GranToxiLux antibody dependent cell-mediated cytotoxicity assay. Cytom. A 93, 436\u2013447 (2018).","journal-title":"Cytom. A"},{"key":"1424_CR55","doi-asserted-by":"publisher","first-page":"310","DOI":"10.4161\/mabs.19873","volume":"4","author":"BS Parekh","year":"2012","unstructured":"Parekh, B. S. et al. Development and validation of an antibody-dependent cell-mediated cytotoxicity-reporter gene assay. MAbs 4, 310\u2013318 (2012).","journal-title":"MAbs"},{"key":"1424_CR56","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41434-020-00214-w","volume":"29","author":"F Yang","year":"2022","unstructured":"Yang, F. et al. Validation of an IFN-gamma ELISpot assay to measure cellular immune responses against viral antigens in non-human primates. Gene Ther. 29, 41\u201354 (2022).","journal-title":"Gene Ther."},{"key":"1424_CR57","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.3389\/fimmu.2019.01851","volume":"10","author":"AL Butler","year":"2019","unstructured":"Butler, A. L., Fallon, J. K. & Alter, G. A Sample-Sparing Multiplexed ADCP Assay. Front. Immunol. 10, 1851 (2019).","journal-title":"Front. Immunol."},{"key":"1424_CR58","unstructured":"European Medicines, A. ICH Q2(R2) Validation of analytical procedures scientific guideline. (2023)."},{"key":"1424_CR59","doi-asserted-by":"publisher","first-page":"e24715","DOI":"10.1016\/j.heliyon.2024.e24715","volume":"10","author":"M Raimo","year":"2024","unstructured":"Raimo, M., Zavoianu, A. G., Meijs, W., Scholten, P. & Spanholtz, J. Qualification of a flow cytometry-based method for the evaluation of in vitro cytotoxicity of GTA002 natural killer cell therapy. Heliyon 10, e24715 (2024).","journal-title":"Heliyon"},{"key":"1424_CR60","doi-asserted-by":"publisher","first-page":"2210961","DOI":"10.1080\/21645515.2023.2210961","volume":"19","author":"JY Hwang","year":"2023","unstructured":"Hwang, J. Y. et al. Cross-reactive humoral immunity of clade 2 Oka and MAV\/06 strain-based varicella vaccines against different clades of varicella-zoster virus. Hum. Vaccin. Immunother. 19, 2210961 (2023).","journal-title":"Hum. Vaccin. Immunother."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01424-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01424-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01424-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:04:39Z","timestamp":1779062679000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01424-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1424"],"URL":"https:\/\/doi.org\/10.1038\/s41541-026-01424-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8121887\/v1","asserted-by":"object"}]},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"15 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"102"}}